Ovagen is a peptide bioregulator targeting liver and gastrointestinal mucosa — a dual-target bioregulator in the Khavinson series, uniquely active in both hepatic parenchymal tissue and the epithelial lining of the gastrointestinal tract. Developed at the St. Petersburg Institute of Bioregulation and Gerontology, Ovagen's peptide sequence was derived from gastrointestinal tissue and activates gene expression programs in both GI mucosal cells and hepatocytes that decline with age and chronic exposure to dietary, microbial, and inflammatory stressors.

The gastrointestinal mucosa is among the most rapidly renewing tissues in the body — the intestinal epithelium replaces itself completely every 3–5 days under physiologically optimal conditions. However, this rapid renewal depends on the proliferative and differentiation capacity of intestinal stem cells (ISCs), the gene expression programs of which are subject to progressive epigenetic silencing with age. As ISC function declines, renewal rate slows, mucosal architecture degrades (reduced villus height, impaired tight junction integrity, diminished mucus layer quality), and the resulting barrier dysfunction drives the chronic low-grade intestinal inflammation that underlies the increasing GI dysfunction, food sensitivities, and systemic inflammatory burden characteristic of gut aging.

Ovagen penetrates the nuclei of GI epithelial cells and intestinal stem cells, binding to histone-DNA complexes and reactivating the transcription of genes that maintain mucosal renewal and integrity: tight junction proteins (claudins, occludins), mucin genes for mucus layer production, antimicrobial peptides for innate luminal immune defense, growth factors supporting epithelial proliferation, and anti-apoptotic factors maintaining stem cell viability. The restoration of these programs rebuilds the mucosal barrier from the epigenetic level up.

The simultaneous hepatic activity of Ovagen complements its GI effects through a functional axis of great importance: the gut-liver axis. The liver receives 70% of its blood supply from the portal circulation draining the intestines — meaning that anything crossing the intestinal barrier (bacterial products, dietary metabolites, inflammatory mediators) passes directly to the liver first. Maintaining intestinal barrier integrity (Ovagen's GI action) directly reduces the chronic portal endotoxemia (bacterial LPS translocation through leaky gut) that drives hepatic inflammation, steatosis, and fibrosis. Ovagen's dual activity addresses both sides of this critical axis.

Animal studies demonstrate that Ovagen treatment improves intestinal mucosal histology (better preserved villi, intact tight junctions, adequate goblet cell density), reduces intestinal permeability markers, and improves hepatic function parameters simultaneously — the expected outcome of a dual GI/hepatic bioregulator. Human clinical work in the Khavinson group has examined Ovagen in aging populations with GI dysfunction, individuals with hepato-biliary disorders, and prevention-oriented protocols. Results include improved GI symptom scores, better tolerability of dietary variety, and normalized liver enzyme panels in follow-up assessments.

Protocol: 1–2mg/day for 10 consecutive days, subcutaneous or intranasal, repeated 2–4 times per year. Ovagen pairs naturally with Livagen (liver-specific) for hepatic coverage reinforcement, and with BPC-157 (GI mucosal healing via growth factor mechanisms) for multi-mechanism gut repair. Pancragen adds pancreatic bioregulator coverage for a complete upper GI system restoration stack.